19.96USD+0.10%Mkt Cap: 1.77B USDP/E: —Last update: 2026-05-26
Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
105.81BDKKP/E 20.4
66.47BUSDP/E 15.5
46.56BEURP/E 30.5
43.89BEURP/E 36.5
39.41BUSDP/E 74.0
32.84BUSD—
32.05BSEKP/E 47.4
Indicators:|
Key Statistics
Company
Market Cap1.77B USD
Enterprise Value1.74B USD
Revenue (TTM)217.17M USD
Gross Profit165.38M USD
Net Income (TTM)-285.42M USD
Revenue/Share2.492 USD
Last Price19.96 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees298
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINUS87164F1057
Valuation
P/E (Trailing)—
P/E (Forward)-95.38
PEG—
EV/EBITDA-7.76
EV/Revenue7.99
P/S8.07
P/B26.75
EPS (TTM)-2.79
EPS (Forward)-0.21
52W Range
8.58567% of range25.59
52W High25.59 USD
52W Low8.585 USD
Profitability
Gross Margin95.96%
Oper. Margin-52.73%
EBITDA Margin-103.04%
Profit Margin-165.60%
ROE-441.62%
ROA-53.88%
Growth
Revenue Growth223.60%
Earnings Growth—
Cash Flow & Leverage
Operating CF-322.98M USD
CapEx (TTM)187.00K USD
FCF Margin-85.65%
FCF Yield-10.54%
Net Debt-15.88M USD
Net Debt/EBITDA0.07
Balance Sheet
Debt/Equity5.34
Current Ratio5.47
Quick Ratio4.90
Book Value/Sh0.7390 USD
Cash/Share4.077 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.2 (Strong Buy)
Target (Mean)39.25 USD
Target Range29.00 USD – 57.00 USD
# Analysts12
Ownership
Shares Out.88.61M
Float79.03M
Insiders1.72%
Institutions116.00%
Short Interest
Short Ratio12.8d
Short % Float22.86%
Short % Out.22.47%
Shares Short19.91M
Short (prev mo.)20.70M
Technical
SMA 5022.52 (-11.4%)
SMA 20019.15 (+4.3%)
Beta0.41
S&P 52W Chg28.31%
Avg Vol (30d)1.63M
Avg Vol (10d)1.58M
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—